Top entities: Santhera Pharmaceuticals, Nxera Pharma, South Korea, South Korea — Ministry of Food and Drug Safety.

What category does this event fall under?

Regulatory — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jun 02, 2026. Coverage continues to evolve.

Regulatory regulatory approval

AGAMREE receives South Korea designations

Q: When did this event occur?

First reported Jun 02, 2026; last updated Jun 02, 2026.

Q: What is the market impact?

Direct. The designations for AGAMREE in South Korea are positive for Santhera Pharmaceuticals and Nxera Pharma, as they accelerate market access and potential revenue streams.

Analysis based on 6 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The designations for AGAMREE in South Korea are positive for Santhera Pharmaceuticals and Nxera Pharma, as they accelerate market access and potential revenue streams. This news could lead to increased investor confidence in both companies, particularly Santhera Pharmaceuticals, which will receive royalties and milestone payments.

Pharmaceuticals Biotechnology

Event Summary

Santhera Pharmaceuticals announced that its drug AGAMREE has received Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation from South Korea's South Korea — Ministry of Food and Drug Safety for the treatment of Duchenne muscular dystrophy (DMD). These designations acknowledge the significant unmet medical need for DMD patients in South Korea, where no alternative treatment is currently available. The GIFT designation is a priority review pathway that could shorten the standard regulatory review timeline from 120 to 90 working days, potentially accelerating patient access to AGAMREE. Nxera Pharma, Santhera's licensing partner, holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. Santhera Pharmaceuticals will receive sales and milestone payments, along with royalties on net sales of AGAMREE in these licensed territories.

Key Actions

80 Nxera Pharma plans to submit

Entities Involved

stock

Santhera Pharmaceuticals

Santhera Pharmaceuticals will receive sales, milestone payments, and royalties from the net sales of AGAMREE in South Korea, Japan, Australia, and New Zealand due to the licensing agreement with Nxera Pharma The Orphan Drug Designation and Global Innovative Products on Fast Track designation for AGAMREE in South Korea are positive developments for the company.

Importance 100 Sentiment 70

stock

Nxera Pharma

Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.

Importance 90 Sentiment 60

cnt

South Korea

South Korea's South Korea — Ministry of Food and Drug Safety granted Orphan Drug Designation and Global Innovative Products on Fast Track designation for AGAMREE, recognizing the unmet medical need for Duchenne muscular dystrophy patients in the country.

Importance 70 Sentiment 0

govactor

South Korea — Ministry of Food and Drug Safety

The South Korea — Ministry of Food and Drug Safety in South Korea granted the Orphan Drug Designation and Global Innovative Products on Fast Track designation to AGAMREE, which will expedite its regulatory review.

Importance 60 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard